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Abstract Chronic hepatitis B is the leading cause of liver
cancer and the largest health disparity between Asian/
Paciﬁc Islanders (APIs) and the general US population.
The Hep B Free model was launched to eliminate hepatitis
B infection by increasing hepatitis B awareness, testing,
vaccination, and treatment among APIs by building a
broad, community-wide coalition. The San Francisco Hep
B Free campaign is a diverse public/private collaboration
unifying the API community, health care system, policy
makers, businesses, and the general public in San Fran-
cisco, California. Mass-media and grassroots messaging
raised citywide awareness of hepatitis B and promoted use
of the existing health care system for hepatitis B screening
and follow-up. Coalition partners reported semi-annually
on activities, resources utilized, and system changes insti-
tuted. From 2007 to 2009, over 150 organizations con-
tributed approximately $1,000,000 in resources to the San
Francisco Hep B Free campaign. 40 educational events
reached 1,100 healthcare providers, and 50% of primary
care physicians pledged to screen APIs routinely for hep-
atitis B. Community events and fairs reached over 200,000
members of the general public. Of 3,315 API clients tested
at stand-alone screening sites created by the campaign,
6.5% were found to be chronically infected and referred to
follow-up care. A grassroots coalition that develops strong
partnerships with diverse organizations can use existing
resources to successfully increase public and healthcare
provider awareness about hepatitis B among APIs, promote
routine hepatitis B testing and vaccination as part of stan-
dard primary care, and ensure access to treatment for
chronically infected individuals.
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Introduction
Chronic infection with hepatitis B virus (HBV) is one of
the largest racial/ethnic health disparities in the United
States. Approximately 10% of foreign-born Asians and
Paciﬁc Islanders (APIs) have chronic hepatitis B, compared
with less than 0.5% of the general US population and less
than 0.2% of non-Hispanic whites [1]. Without appropriate
monitoring and treatment, one in four individuals with
chronic hepatitis B will die from liver cancer or liver
failure [2]. Many of these deaths are preventable through
hepatitis B vaccination, which has been available since
1982, and anti-viral therapy, which reduces the risk of
progression from chronic hepatitis B to liver cancer [3].
Liver cancer mortality may also be reduced through routine
liver screening to enable early diagnosis and treatment [4].
To beneﬁt from liver cancer preventive measures, one
must ﬁrst be diagnosed with chronic hepatitis B. Because
the vast majority of chronically infected individuals have
no symptoms, the only reliable method to diagnose chronic
hepatitis B is with a serologic (i.e., blood-based) test for
hepatitis B surface antigen (HBsAg). Likewise, the only
way to ensure that an individual is protected against hep-
atitis B is with a serologic test for hepatitis B surface
antibody (anti-HBs). The US Centers for Disease Control
and Prevention (CDC) recommends routine hepatitis B
testing for all individuals born in regions with an inter-
mediate or high population seroprevalence of HBsAg—
including all of Asia and the Paciﬁc Islands—as well as
US-born individuals not vaccinated in infancy whose par-
ents were born in regions of high HBsAg seroprevalence
[5]. Because two-thirds of APIs in the US are foreign-born
[6], and more than three-quarters of US-born APIs have
parents born in Asia or the Paciﬁc Islands [7], virtually all
APIs should be routinely tested for hepatitis B.
However, the CDC recommendations are not widely
known or followed, and testing coverage among APIs is
inadequate. For instance, 30% of primary care providers in
San Francisco prior to 2007 could not correctly identify the
screening test for hepatitis B, and most were unaware of
the disproportionate burden of chronic infection among
Chinese immigrants [8]. Among New Jersey family phy-
sicians, more than 70% did not routinely perform liver
cancer screening among patients with chronic hepatitis B,
and only 50% followed the CDC recommendation for
hepatitis B testing in household contacts of persons with
chronic infection [9]. Even among Asian American
primary care physicians, less than one third reported rou-
tinely testing their API patients for hepatitis B [10].
A similar lack of awareness about hepatitis B is also
seen in the general public: up to two-thirds of chronically
infected APIs are unaware of their infection status [11].
Community studies have consistently demonstrated low
knowledge about hepatitis B risks, transmission, and pre-
vention among APIs [11–23], and some studies showed
that fewer than half of API adults had ever been tested or
vaccinated, with especially low rates in socioeconomically
disadvantaged populations [13, 16–18, 20, 24]. These
ﬁndings demonstrate the need for broad-based strategies,
including culturally tailored educational materials and
media campaigns, to engage the API community in
addressing hepatitis B.
To overcome existing barriers, the San Francisco Hep B
Free campaign (SFHBF) was launched in 2007 to increase
hepatitis B awareness, testing, vaccination, and treatment
among APIs by forming a community coalition to educate
health care providers and the general population, and to
provide access to low-cost hepatitis prevention. In this
report, we describe campaign activities and results through
2009, with the goal of demonstrating the success of Hep B
Free and sharing methods used so that this program can be
adapted by other communities.
Methods
Mission and Guiding Principles
The mission of SFHBF is to make San Francisco the ﬁrst
hepatitis-B-free city in the nation. The objectives of
SFHBF are: (1) to create public and health care provider
awareness about the importance of testing and vaccination
to decrease the burden of hepatitis B in the API commu-
nity; (2) to promote routine hepatitis B testing and vacci-
nation, and make them the standard of care in the primary
medical community; and (3) to ensure access to treatment
for chronically infected individuals. To accomplish these
objectives, the program uses culturally targeted strategies
to increase hepatitis B testing, vaccination, and treatment
services in the high-risk API community; and it promotes
general knowledge about hepatitis B to create broad public
awareness and institutional change toward ending hepatitis
B infection.
SFHBF was designed as a grassroots, community-based
health initiative with these guiding principles: (1) to
maximize use of existing resources and community orga-
nizations, rather than to create a new standalone institution;
(2) to be self-sustaining and integrated into the existing
health care system; (3) to adopt practices that could be
readily replicated elsewhere; (4) to pursue all available
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123funding opportunities, but not wait for funding before
taking action; (5) to remain focused on the primary goal of
hepatitis B control; (6) to reﬂect and take advantage of
speciﬁc characteristics of the API community, and (7) to
use a multi-faceted approach targeting the API community,
the health care system, policy makers and public ofﬁcials,
and the general public. Many of these guiding principles
follow the theoretical framework of Community Coalition
Action Theory [25], which posits that through collabora-
tion and synergy, community coalitions can bring about
changes that the contributing members would be unable
and, often, unwilling to accomplish individually [26].
San Francisco possesses unique characteristics that
served as both an impetus and a challenge to the initiation
of SFHBF. APIs comprise one-third of San Francisco’s
nearly 800,000 residents, and 67% of those APIs are for-
eign-born [6]. At the county level, San Francisco has the
highest incidence rate of liver cancer in the nation [27].
Because 91% of API adults in San Francisco have health
insurance [28], SFHBF could function within existing
medical infrastructure by encouraging people to visit their
regular health care provider for hepatitis B testing, vacci-
nation, and follow-up.
Steering Committee Formation
In April 2007, SFHBF was launched after 6 months of
strategic planning by the founding Steering Committee.
This committee’s makeup reﬂects the depth and breadth of
experience among partners in the campaign, and includes a
specialist in health promotion (from the San Francisco
Department of Public Health [SFDPH]), an academic and
clinical expert on hepatitis B and liver cancer (from the
Asian Liver Center at Stanford University [ALC]), and an
API community and media leader (from the AsianWeek
Foundation [AWF]).
SFDPH has been involved in hepatitis B prevention and
detection efforts since the 1990s. In 1997, SFDPH perma-
nently allocated general funds to purchase adult hepatitis B
vaccine for distribution to clinics and other community
partners serving low-income, uninsured patients. SFDPH’s
commitment to SFHBF was critical for enlisting involve-
ment of other health care players, adding legitimacy to
interactions with community groups and the public, and
contributing expertise in health promotion and education.
SFDPH houses all data collected for SFHBF, and oversees
campaign documentation and evaluation efforts.
ALC was established at Stanford University in 1996 as
the ﬁrst non-proﬁt organization devoted to addressing
chronic hepatitis B and liver cancer among APIs. ALC
provides SFHBF with expertise in hepatitis B outreach,
education, advocacy, and community-based research. In
2004, ALC partnered with SFDPH to launch ‘‘3 For Life,’’
a 1-year pilot program that offered semi-monthly hepatitis
B testing and vaccination for a discounted fee at a non-
clinical community setting in San Francisco. The results of
this project offered proof of the need for expanded hepatitis
B testing and education for San Francisco APIs [29].
AWF was founded in 2004 to organize and develop the
API community. AWF provides SFHBF with strategic and
tactical expertise on mobilizing the community to action.
AWF also provides media expertise in reaching the API
and general markets, understanding of the nuanced cultural
protocols of the API community, and using community
networks to engage public ofﬁcials. In 2006, AWF invited
ALC to the Asian Heritage Street Celebration in San
Francisco to conduct the largest ever one-day hepatitis B
screening event, at which 536 adults were screened in 5 h.
Over the next few months, AWF brought together the San
Francisco Health Commission and California Assembly
Speaker Pro Tempore Fiona Ma to share the vision for
universal hepatitis B screening for API adults. These dis-
cussions led to the creation of the Hep B Free model.
Fiona Ma was a San Francisco Supervisor in 2006, when
she authored a resolution unanimously approved by the
Board of Supervisors ‘‘establishing the goal of universal
hepatitis B screening and vaccination for Asian and Paciﬁc
Islander residents of San Francisco.’’ Ms. Ma, who herself
is chronically infected with hepatitis B, provided leadership
and motivation for SFHBF by publicly discussing her own
experience with hepatitis B. She has become a national
spokesperson for hepatitis B awareness, prevention, and
detection efforts, and provides SFHBF with guidance on
policy making and assistance with motivating high-level
decision makers in public and private organizations to take
more active roles as SFHBF partners.
Before ofﬁcially launching SFHBF, the Steering Com-
mittee established certain minimum infrastructure
requirements, including the campaign’s name, mission,
project description, website, and logo, and conducted basic
research on the size, demographic characteristics, and
health insurance coverage of the at-risk population.
Formation of Partnerships
The Steering Committee ﬁrst conducted preliminary
meetings and conversations with health care, industry, and
community groups to assess interest in and feedback on a
community-wide hepatitis B control effect. This process
identiﬁed key issues, needs, and messages to ensure buy-in
from key stakeholders and constituencies. In addition, the
Steering Committee sought strong advocacy by garnering
the support of high-proﬁle leaders including Ms. Ma and
San Francisco Mayor Gavin Newsom.
Obtaining commitments from all public and private
county hospitals was critical to the campaign’s success.
540 J Community Health (2011) 36:538–551
123Hospitals and clinics were initially approached individu-
ally, after which the Steering Committee presented col-
lectively to hospital chief executive ofﬁcers at the San
Francisco Hospital Council, a regional trade association.
Each hospital took on a different role in SFHBF, with no
single hospital designated as leader. By mid-2007, all San
Francisco hospitals had pledged to prioritize elimination of
hepatitis B. SFDPH committed to providing follow-up care
to uninsured patients with chronic hepatitis B, and Hospital
Council members pledged back-up support. In addition,
health care institutions coordinated to create public hepa-
titis B testing and vaccination sites in the community,
arrange continuing medical education courses, network
with corporate sponsors, and perform research on hepatitis-
B-related health care.
Non-health-care community partners, including virtually
every local API community group, were recruited or vol-
unteered to join the campaign by incorporating hepatitis B
prevention into their own program as appropriate with their
existing mission and resources. This integration encour-
aged increased participation and ownership by each partner
organization, while the absence of minimum ‘‘member-
ship’’ requirements enabled partners to contribute at
whatever level was practical. For example, local merchants
distributed SFHBF branded shopping bags, while two local
colleges instituted campus-wide education, screening, and
vaccination programs for all students, staff, and faculty.
Community partners helped to disseminate campaign
messages in culturally effective ways and ensure that the
activities and policies of the campaign reﬂected community
needs and cultural practices.
A core group of approximately 40 organizations have
been considered as active partners that participate in
monthly working meetings to plan strategies, implement
activities, share resources and best practices, report on
progress, and request assistance when necessary (Table 1).
Speciﬁc tasks are accomplished by separate working
groups with designated point persons. Active partners
complete a survey every 6 months to detail their involve-
ment via activities, expenses incurred, and services pro-
vided. The remaining community partners participate by
attending and supporting SFHBF events and disseminating
educational information via their own networks.
Funding
SFHBF was conceptualized and launched with no formal
funding source. Each participating organization ﬁnds its
own funding for its own programs. SFHBF uses a neutral
ﬁscal agent to manage funds, and raises funds only for
public awareness and education efforts, community out-
reach, and program evaluation. The campaign secured
Table 1 Actively participating partner organizations of the San
Francisco Hep B Free Campaign, 2007–2010
Alison Public Relations
American Legion Cathay Post 384
American Liver Foundation
Asian Health Foundation
Asian Liver Center at Stanford University
Asian & Paciﬁc Islander Health Parity Coalition
Asian Paciﬁc Islander Wellness Center
AsianWeek Foundation
Brown & Toland Physicians Group
California Paciﬁc Medical Center
Catholic Healthcare West
Chinatown Public Health Center
Chinese American Physicians Association
Chinese Community Healthcare Association
Chinese Hospital
City College of San Francisco
DAE advertising
Excelsior Health Services
Glide Health Services
interTrend Communications, Inc
Kaiser Permanente San Francisco
Laotian American National Alliance
Miss Asian American Pageant
NICOS Chinese Coalition
Niwa Public Relations
North East Medical Services
Ofﬁce of Mayor Gavin Newsom
Ofﬁce of California Assemblywoman Fiona Ma
Saint Francis Memorial Hospital
San Francisco Board of Supervisors
San Francisco Community Clinic Consortium
San Francisco Department of Public Health
San Francisco General Hospital Liver Center
San Francisco Giants
San Francisco Hep B Collaborative at Berkeley
San Francisco Hospital Council
San Francisco Medical Society
San Francisco State University
South of Market Health Center
St. Luke’s Hospital
St. Mary’s Medical Center
St. Anthony’s Free Medical Clinic
Subaru of America
Sunset Health Services
Sutter Health
University of California, San Francisco Liver Center
University of California, San Francisco Hepatitis B Collaborative
University of California, San Francisco Vietnamese Community Health
Promotion Project
Walgreens
Active partners participated in monthly meetings and working groups
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123nearly $2.5 million through 2009 in direct and in-kind
donations from partners, government agencies, corpora-
tions, and private donors, as well as approximately 8,000
volunteer hours. Sources of funds include community
fundraising events, corporate sponsorships, and grants from
foundations, corporations, and the federal government.
Promotion of Education and Awareness
To incorporate routine hepatitis B testing of all API
patients into standard health care, education of health care
providers is essential. SFHBF began educating providers
through ongoing grand rounds and continuing medical
education events throughout the city. In addition, a physi-
cian working group collaboratively developed a quick-
reference hepatitis B diagnostic ﬂowchart for testing, test
interpretation, and clariﬁcation of common misconceptions
about hepatitis B and liver cancer. To further engage
physicians, all health care providers in the city were asked
to sign a pledge form stating that they would follow the
CDC recommendations to test every API patient for hep-
atitis B. Physicians were contacted by sending fax mes-
sages from SFDPH, making telephone calls to physicians’
ofﬁces, recruiting physician champions from each health
care institution, and networking through medical groups
and independent practice associations.
General community awareness about hepatitis B was
promoted through grassroots community organizing, out-
door advertising on billboards, taxi tops, train stations, and
bus panels and shelters, and advertising and news coverage
in major mass-media covering the general and Asian print,
radio, television, and internet markets (Fig. 1). Advertising
campaigns were designed pro bono by leading Asian
American advertising agencies. Media placements were
funded through in-kind donations and cash in an approxi-
mately4:1ratio.Educationalmaterials,includingbrochures,
posters, and public service announcements, were translated
into Cantonese and Mandarin Chinese, English, Korean,
Tagalog, and Vietnamese by local API media and medical
students and undergraduates with background knowledge of
hepatitisB.SFHBF’scommunityinvolvementalsoprovided
unique access to public ofﬁcials. SFHBF leaders worked
with community advocacy groups, policymakers, and lob-
byists to promote opportunities for legislative or regulatory
changes regarding hepatitis B prevention, management, and
research.
Serological Testing, Vaccination, and Referrals
A key component of SFHBF is provision of testing, vac-
cination, and follow-up for hepatitis B through existing
health care providers. Hospital and clinic-afﬁliated testing
and vaccination sites were funded, staffed, and managed by
their independent institutions. Seven standalone public
sites providing free hepatitis B testing and low-cost vac-
cination were established throughout the city beginning in
2007. These sites supplemented rather than replaced pri-
vate providers or clinics, by making services more con-
venient for those with existing primary care, and to ﬁll an
unmet need for those without health insurance. Sites were
manned by bilingual hospital/clinic staff and trained vol-
unteers. Each site was separately managed according to its
host institution’s infrastructure.
At the outset, clinical partners convened to agree on
overall goals and strategies, establish minimum standard-
ized testing and vaccination protocols, and deﬁne the basic
data points on participant registration forms. Each partner
site informed clients about their serological test results and
recommended follow-up steps using a variety of methods.
Clients found to be protected against hepatitis B were sent
letters, while susceptible clients (who were advised to be
immunized against hepatitis B) or chronically infected
Fig. 1 Examples of San
Francisco Hep B Free
advertising campaign materials.
a Bus side advertisement with
San Francisco Mayor Gavin
Newsom and California State
Assemblywoman Fiona Ma.
b ‘‘B a Hero’’ Bay Area Rapid
Transit poster. c ‘‘B a Hero’’
promotional vehicle donated by
Subaru of America. d ‘‘Which
One Deserves to Die?’’
campaign poster featuring
beauty pageant contestants
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123clients (who were advised to seek follow-up medical care)
were contacted via a combination of letters, phone calls,
e-mail, and in-person appointments.
Data Collection and Analysis
At each testing/vaccination site, clients completed a stan-
dardized registration form providing basic demographic and
health-related information. By request, hospital laboratories
and independent diagnostic laboratories serving San Fran-
cisco provided data on the total number of HBsAg and anti-
HBstestsorderedannually.Resultsfrompartnersurveysand
patient registration forms were analyzed using SAS version
9.1.3 (Cary, NC). We used logistic regression analysis to
estimate unadjusted or multivariate adjusted odds ratios for
associations with HBsAg positivity or anti-HBs negativity.
All tests of signiﬁcance were two-sided, and p-val-
ues B 0.05 were considered statistically signiﬁcant.
Results
Community Partnerships
SFHBF ofﬁcially commenced in April 2007 with a com-
munity dinner with nearly 500 attendees representing over
150 community groups that pledged support for the cam-
paign. Invited groups included hospitals, health care
organizations, community-based organizations, academic
institutions, student groups, professional societies, social
service agencies, government agencies, media and adver-
tising companies, and corporations. Additional partners
asked to join the campaign or were recruited over time. As
of 2010, more than 160 groups are partners in SF HepB
Free, including more than 40 active partners (listed at
http://sfhepbfree.org/aboutus/ and in Table 1).
Amongthe24majorpartnerorganizationsthatcompleteda
surveyattheendof2009,13(57%)werefromthehealthcare
sector, 4 (17%) were academic institutions, 3 (13%) were
communityorganizations,3(13%)weremediaorganizations,
and 1 was a government representative. Ten partners con-
tinuously offered free HBsAg screening and referrals to
follow-up care for chronically infected patients; 9 conducted
additional one-time community screening clinics at cultural
festivals and other events; 6 provided continual free or low-
cost hepatitis B vaccination; 10 participated in fundraising; 7
were involved in public outreach and marketing; and 5 con-
ducted educational events for health care providers.
These 24 partner organizations raised $1,274,000,
including 85% from grant funding, to support SFHBF
activities, and spent approximately $2,752,000 on the
campaign, including $1,270,000 (46%) for paid staff,
$670,000 (24%) for marketing, $272,300 (10%) for
supporting volunteers (who contributed 8,000 h), $124,000
(5%) for laboratory costs, $64,000 (2%) for vaccinations,
and $340,000 on other expenses such as travel and venue
rental fees.
Education and Awareness Programs
Between 2007 and 2009, more than 40 educational events
on hepatitis B were held, reaching over 1,100 health care
providers in the city. In addition, laminated hepatitis B
diagnostic ﬂowcharts were distributed by SFDPH to all
primary care physicians as a resource for hepatitis B test-
ing. Among primary care physicians asked to sign a
statement pledging to test all APIs for hepatitis B, 60% did
so and were listed by name in a ‘‘Clinical Honor Roll’’
published regularly in local general and ethnic print media.
SFHBF partners published 280 billboards and bus pan-
els, 488 newspaper public service announcements (PSAs),
62 television PSAs, 1,240 radio PSAs, 72 newsletters, 63
website banners and advertisements, and e-mail messages
that reached an estimated 260,000 readers. In addition,
campaign partners hosted informational booths, gave pre-
sentations, and distributed ﬂyers and souvenirs at more
than 120 community events, including street fairs, cultural
shows, fashion shows, conference presentations, and
classroom seminars; total attendance was approximately
200,000 people. Because community demonstrations and
rallies are less culturally favored activities for the API
community, SFHBF organized community banquets as a
more culturally appropriate, intergenerational forum for
increasing hepatitis B awareness.
Client Survey Results
At the seven public standalone SFHBF testing and vacci-
nation sites, most clients were between ages 18 and
50 years, and 61% were female. Eighty percent were of
API background, including 55% Chinese, and just over half
spoke primarily in an Asian language only (Table 2). More
than two-thirds of clients at the standalone sites were for-
eign-born, and 60% of those born in North America had at
least one foreign-born parent. Only 18% reported ever
having received immunization shots for hepatitis B, and
4% reported having previously been diagnosed with hep-
atitis B. The majority (59%) of clients had current health
insurance, although fewer than half (46%) reported having
a current medical provider.
Serologic Testing Results
At the seven standalone SFHBF testing and vaccination
sites, 4,427 clients were serologically tested for HBsAg
and anti-HBs, including 3,315 clients of API background.
J Community Health (2011) 36:538–551 543
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123Among the APIs, 6.5% (N = 224) were chronically
infected, 41.6% (N = 1,381) were susceptible, and
51.9% (N = 1,719) were immune (Table 2). When the
serological results were further restricted to the 2,639
API clients born in Asia, 7.9% (N = 208) were chroni-
cally infected.
Of note, among clients who provided information on
whether or not they had already been diagnosed with
hepatitis B by a doctor, 66 of 147 (44.9%) chronically
infected individuals reported that they had not previ-
ously been diagnosed, and 29 of 147 (19.7%) were
unsure whether they had been diagnosed. Thus, up to
two-thirds of clients with chronic hepatitis B were
previously unaware of their infection. In addition, 16 of
655 clients (2.4%) who reported having received
immunization shots for hepatitis B were in fact chron-
ically infected.
After mutual adjustment, we found that being between
ages 41 and 60 years, male, of API background, born
outside North America, and without a current medical
provider were statistically signiﬁcantly associated with a
higher risk of being chronically infected with hepatitis B
(Table 3). In addition, individuals who had not received
hepatitis B immunization shots, had previously been
diagnosed with hepatitis B by a doctor, or had a family
history of hepatitis B were at signiﬁcantly elevated risk of
chronic infection. Factors associated with a higher risk of
being unprotected against hepatitis B were older age, birth
outside Asia and the Paciﬁc Islands, and a non-Asian pri-
mary spoken language (Table 3). Results were essentially
unchanged when the analysis was restricted to API clients
(data not shown).
Laboratory Results
At all hospital and independent diagnostic laboratories
serving San Francisco, 69,821 tests for HBsAg and 54,340
tests for anti-HBs were ordered in 2006, the year before
SFHBF was launched. In 2007, 72,678 tests for HBsAg (a
4% increase over 2006) and 56,001 tests for anti-HBs (a
3% increase over 2006) were ordered. In 2008, 75,122 tests
for HBsAg (an 8% increase over 2006) and 63,462 tests for
anti-HBs (a 17% increase over 2006) were ordered.
Follow-Up Results
Based on reports from the seven standalone SFHBF testing
and vaccination sites, 69% of clients found to be chroni-
cally infected were enrolled in follow-up clinical care. Of
nearly 2,000 clients found to be susceptible, 52% received
at least the ﬁrst shot of hepatitis B vaccine, and 49% of
these completed the three-shot vaccine series at one of the
standalone sites.
Discussion
Our results show that SFHBF successfully established a
dedicated community network to increase hepatitis B
knowledge, testing, vaccination, and follow-up in San
Francisco. Critical to success was inclusion of a diverse
array of partners, including all hospitals, other health care
and public health entities, and dozens of partners with
expertise in non-health-related areas, including both API
and non-API organizations. We believe that several strat-
egies were integral to the promotion of effective collabo-
ration among these partners: (1) delineating and sharing
collective goals and protocols, (2) distributing leadership
responsibilities, (3) ﬁnding appropriate roles that matched
partners’ skills and expertise, (4) encouraging partners’
ownership of key issues and actions, (5) recognizing each
partner’s contributions, and (6) continuously reaching out
to ﬁnd new, complementary partners. These aspects of
SFHBF correspond to coalition-building factors that have
been found to be consistently effective, namely, formal-
ization of procedures, strong leadership, active member-
ship participation, membership diversity, collaboration
among member agencies, and group cohesion [30].
Community coalitions such as SFHBF can be evaluated
at three levels: the level of infrastructure, function, and
processes; the level of programs and interventions; and the
level of community changes [26]. The ﬁrst level, internal
coalition functioning, can be assessed in terms of the size
of the coalition membership, the number of people reached
by coalition efforts, the number of actions implemented,
and member satisfaction with coalition functioning, all of
which aim to evaluate the process of community building
[26, 30, 31]. Evidence of the successful infrastructure and
functioning of SFHBF comes from its engagement of more
than 160 community partners, more than 40 of which
voluntarily meet on a monthly basis; and its completion of
more than 40 physician education events and 120 com-
munity events, which reached over 1,100 health care pro-
viders and 200,000 community members, respectively, in
only 2 years. High levels of participation in monthly
partner meetings may be attributable in part to thoughtful
planning and scheduling, as well as promoting a collegial
atmosphere with active solicitation of input, offering of
constructive feedback and recognition of contributions, and
transparent sharing of information and resources.
The second level of evaluation, implementation of
coalition programs and activities, can be evaluated based
on the extent to which speciﬁc program objectives are met,
using data from such sources as hospital or clinic records
and patient surveys [26]. Results from all laboratories
serving San Francisco indicate a steady increase in hepa-
titis B testing from 2006 through 2008, suggesting con-
siderable progress toward our objectives of increasing
J Community Health (2011) 36:538–551 547
123Table 3 Associations of demographic and health-related characteristics with hepatitis B infection status among clients tested at standalone
San Francisco Hep B Free sites
Characteristic Infected vs. immune Susceptible vs. immune
Unadjusted Adjusted Unadjusted Adjusted
OR 95% CI P-value OR* 95% CI* P-value OR 95% CI P-value OR
 95% CI
 P-value
Age (years)
\30 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
31–40 2.3 (1.5, 3.6) 1.4 (0.9, 2.2) 2.3 (1.9, 2.8) 2.8 (2.3, 3.5)
41–50 3.3 (2.2, 5.0) 1.8 (1.2, 2.8) 2.9 (2.4, 3.6) 3.8 (3.1, 4.7)
51–60 2.5 (1.7, 3.6) 1.5 (1.0, 2.3) 2.2 (1.9, 2.7) 3.0 (2.5, 3.6)
61? 1.7 (1.1, 2.7) \0.0001 1.1 (0.7, 1.8) 0.06 2.3 (1.9, 2.8) \0.0001 3.3 (2.7, 4.1) \0.0001
Sex
Female 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Male 1.9 (1.5, 2.5) \0.0001 1.8 (1.3, 2.3) \0.0001 1.2 (1.0, 1.3) 0.02 1.1 (1.0, 1.2) 0.18
Race/ethnicity
Chinese 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Filipino 0.4 (0.2, 0.8) 0.6 (0.3, 1.2) 1.0 (0.8, 1.3) 1.0 (0.7, 1.4)
Vietnamese 1.3 (0.8, 2.0) 1.4 (0.7, 2.5) 0.7 (0.5, 0.9) 0.8 (0.6, 1.1)
Other Asian/Paciﬁc
Islander
0.8 (0.4, 1.6) 0.8 (0.4, 1.9) 0.9 (0.7, 1.3) 1.0 (0.6, 1.5)
Non-Asian/Paciﬁc
Islander
0.2 (0.1, 0.4) \0.0001 0.4 (0.2, 0.9) 0.007 1.5 (1.3, 1.8) \0.0001 1.2 (0.8, 1.6) 0.08
Region of birth
East Asia 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
North America 0.1 (0.08, 0.2) 0.3 (0.1, 0.5) 1.3 (1.1, 1.5) 1.3 (1.0, 1.6)
SE Asia/Paciﬁc Islands 1.0 (0.7, 1.4) 1.1 (0.7, 1.7) 1.1 (0.9, 1.3) 1.0 (0.8, 1.2)
Other 0.7 (0.3, 1.3) \0.0001 1.5 (0.6, 3.9) 0.0001 1.9 (1.4, 2.5) \0.0001 1.7 (1.2, 2.5) 0.01
Mother’s region of birth
East Asia 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
North America 0.04 (0.01, 0.3) 0.3 (0.03, 2.2) 1.6 (1.3, 2.0) 1.2 (0.9, 1.6)
SE Asia/Paciﬁc Islands 0.8 (0.6, 1.2) 1.1 (0.6, 2.0) 0.9 (0.8, 1.1) 0.9 (0.7, 1.2)
Other 0.6 (0.3, 1.2) 0.0009 1.5 (0.4, 5.4) 0.36 1.6 (1.2, 2.1) \0.0001 1.0 (0.7, 1.6) 0.54
Father’s region of birth
East Asia 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
North America 0.1 (0.02, 0.3) 0.5 (0.1, 2.2) 1.4 (1.1, 1.7) 0.9 (0.7, 1.2)
SE Asia/Paciﬁc Islands 0.7 (0.5, 1.0) 0.9 (0.5, 1.5) 0.9 (0.7, 1.0) 0.8 (0.6, 1.1)
Other 0.5 (0.2, 1.1) \0.0001 1.5 (0.4, 5.4) 0.42 1.5 (1.1, 2.0) 0.0003 0.9 (0.6, 1.4) 0.62
Number of years in United States
0–5 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
6–10 1.1 (0.7, 1.7) 1.0 (0.6, 1.6) 1.2 (0.9, 1.6) 1.1 (0.8, 1.4)
11–20 0.8 (0.5, 1.2) 0.8 (0.5, 1.2) 1.2 (1.0, 1.5) 1.0 (0.8, 1.2)
21? 0.8 (0.5, 1.2) 0.7 (0.5, 1.1) 0.36 1.6 (1.2, 1.9) 1.0 (0.8, 1.3) 0.98
(Born in North America) 0.1 (0.07, 0.2) \0.0001 (Not estimated) 1.5 (1.2, 1.8) 0.0004 (Not estimated)
Primary language
Asian language only 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
English only 0.1 (0.1, 0.3) 0.5 (0.2, 1.2) 1.5 (1.3, 1.8) 1.7 (1.4, 2.2)
Asian ? English/other
language
0.4 (0.3, 0.6) 0.7 (0.4, 1.0) 1.2 (1.1, 1.4) 1.6 (1.3, 1.9)
Other/Multiple 0.5 (0.2, 1.0) \0.0001 1.2 (0.3, 4.3) 0.17 1.4 (1.1, 1.9) \0.0001 1.5 (1.0, 2.2) \0.0001
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123public and health care awareness and incorporating sero-
logical testing for hepatitis B into standard primary medical
care. Because SFHBF was designed to encourage individ-
uals to seek hepatitis B testing and follow-up through their
own health care providers, we anticipate that the largest
impact of SFHBF on hepatitis B preventive activity was
seen in hospitals and doctors’ ofﬁces. However, we could
not collect patient data from these sources. From the seven
standalone testing and vaccination sites, which represent a
small subset of individuals who undertook hepatitis B
preventive activity as a result of SFHBF, we collected data
on 4,427 clients who were tested for hepatitis B during the
ﬁrst 2 years of the campaign. In accordance with the
campaign’s goals and strategies, these individuals were
mostly of API background, but encompassed a wide range
of ages, ethnicities, languages, and immigration histories,
and included the insured and uninsured, thus meeting our
objective of ensuring access to testing, vaccination, and
treatment for all individuals.
Data fromthe sevenstandalonesites were consistentwith
previous hepatitis B screening studies in API communities
[11, 23, 32] and conﬁrmed common misunderstandings
regarding chronic hepatitis B infection and vaccination. We
usedtheseﬁndingstoimproveoureducationalmaterialsand
programsforthegeneralpublicandforhealthcareproviders.
However, we lacked information on changes in hepatitis-B-
related knowledge as a result of these educational materials
and programs, and were therefore unable to evaluate the
success of these approaches. Nevertheless, previous studies
using highly similar educational materials and programs
resultedinsigniﬁcantincreasesinknowledgeabouthepatitis
B among health care providers [33] and the general
Table 3 continued
Characteristic Infected vs. immune Susceptible vs. immune
Unadjusted Adjusted Unadjusted Adjusted
OR 95% CI P-value OR* 95% CI* P-value OR 95% CI P-value OR
 95% CI
 P-value
Ever received shots for hepatitis A
No 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Yes 0.4 (0.2, 0.7) 0.7 (0.4, 1.2) 0.5 (0.4, 0.7) 0.5 (0.4, 0.7)
Not sure 0.4 (0.3, 0.6) \0.0001 0.6 (0.4, 0.8) 0.002 0.6 (0.6, 0.7) \0.0001 0.7 (0.6, 0.9) \0.0001
Ever received shots for hepatitis B
No 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Yes 0.2 (0.1, 0.3) 0.2 (0.1, 0.4) 0.3 (0.3, 0.4) 0.3 (0.3, 0.4)
Not sure 0.4 (0.3, 0.5) \0.0001 0.5 (0.4, 0.7) \0.0001 0.6 (0.5, 0.7) \0.0001 0.7 (0.6, 0.8) \0.0001
Ever diagnosed with hepatitis B by a doctor
No 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Yes 23.4 (14.2, 38.5) 19.7 (11.5, 33.7) 0.4 (0.2, 0.8) 0.4 (0.2, 0.8)
Not sure 2.3 (1.4, 3.6) \0.0001 2.0 (1.3, 3.3) \0.0001 0.9 (0.7, 1.2) 0.02 1.0 (0.8, 1.3) 0.06
Family history of hepatitis B
No 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Yes 2.7 (1.8, 4.1) 2.5 (1.6, 3.9) 0.7 (0.5, 0.9) 0.8 (0.6, 1.0)
Not sure 1.3 (0.9, 1.8) \0.0001 1.3 (0.9, 1.9) 0.0002 0.8 (0.7, 0.9) 0.002 0.9 (0.8, 1.1) 0.13
Current health insurance
No 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Yes 0.5 (0.4, 0.7) 0.9 (0.6, 1.3) 1.1 (0.9, 1.2) 0.9 (0.8, 1.1)
Not sure 0.5 (0.2, 1.2) \0.0001 1.0 (0.4, 2.6) 0.008
 0.9 (0.6, 1.3) 0.66 0.9 (0.6, 1.4) 0.79
Current medical provider
No 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Yes 0.5 (0.4, 0.8) 0.6 (0.4, 0.9) 1.3 (1.1, 1.5) 1.0 (0.8, 1.2)
Not sure 0.5 (0.2, 1.1) \0.0001 0.7 (0.3, 1.6) \0.0001 0.7 (0.5, 1.0) \0.0001 0.8 (0.5, 1.1) \0.0001

OR odds ratio, CI conﬁdence interval
* Adjusted for age, sex, race/ethnicity, region of birth, and current medical provider status
 Adjusted for age, region of birth, and primary language
 Having missing information was statistically signiﬁcantly associated with the outcome (data not shown)
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123population [19, 34]. Therefore, we expect that our educa-
tional efforts were successful in achieving our objective of
increasing provider and public awareness about the impor-
tance of hepatitis B testing and vaccination to reduce the
burden of this disease among APIs. We are now in the pro-
cess of evaluating this aspect of the campaign.
The third level of coalition evaluation, community
impact, can be measured by the coalition’s inﬂuence on
progressive changes in local agencies, programs, services,
or policies, as well as increases in the community’s
capacity to solve collective problems [26, 30]. One of
SFHBF’s ﬁrst accomplishments was to enlist every hospital
in San Francisco to join the campaign by prioritizing the
elimination of hepatitis B and contributing to the goals of
the campaign. For many hospitals, this commitment rep-
resented a new advance in services and policies, and pro-
vided immediate evidence of the community impact of
SFHBF. For the overall community, the campaign dem-
onstrates the capacity of San Francisco’s hospitals, com-
munity-based organizations, academic institutions, service
agencies, government agencies, and businesses to come
together and collaborate on solving the shared problem of
hepatitis B. Even more noteworthy is the exceptional gal-
vanization of the API community around a relevant health
issue, a response that has not previously been seen on this
scale. Further evidence of the public impact of SFHBF
comes from recent national news coverage of SFHBF and
hepatitis B prevention [35–37], as well as the replication
of SFHBF in ﬁve other California counties and Chicago,
Las Vegas, Hawaii, Philadelphia, and Washington, DC.
Initial limitations of SFHBF became strengths over
time. For example, the lack of set-aside funding created
early challenges and a dependence on volunteerism and
self-motivation by partners. However, this lack of funding
can now be considered an advantage, forcing the use of
existing resources to establish a stable, sustainable program
that does not rely on time-limited grants or sponsorships,
and is not a new institution requiring separate ongoing
support. Likewise, the decentralized structure of SFHBF
and its reliance on partner involvement may have slowed
and complicated some decision-making and assignment of
responsibilities, but these features have also allowed part-
ners to be autonomous and self-motivated, fostered inte-
gration of the campaign’s mission and objectives with
those of its partners, and ultimately resulted in solid, long-
term commitment by the partners.
Another limitation of SFHBF is the shortage of data for
evaluation of its impact. Evaluation of community coali-
tions, including SFHBF, is often challenging because the
vast majority of energy and funding is spent on planning
and implementing interventions [26]. As a result, evalua-
tion strategies are not built into the planning process and
are not adequately funded.
In summary, SFHBF is a grassroots community coalition
that used existing resources and strong partnerships with
diverse community organizations to successfully increase
public and health care provider awareness about hepatitis B
among APIs, promote routine hepatitis B testing and vacci-
nation as part of standard primary care, and ensure access to
treatment for chronically infected individuals. The absence
of dedicated funding and a single designated leader makes it
feasibletoreplicatethisprograminothercommunitieswitha
high burden of chronic hepatitis B. The prominent health
disparity due to hepatitis B and its often fatal consequences,
the availability of simple steps to detect, prevent, and man-
age the disease, and the current deﬁciency of hepatitis B
awareness and preventive activity among health care pro-
viders and the general public combine to present an unas-
sailable case for making elimination of hepatitis B a top
public health priority. The universal appeal and logic of this
message are what united more than 160 partners of SFHBF,
and will bring together similar community coalitions to
address hepatitis B in communities around the country.
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